Kura Oncology, Inc. (KURA)

We are a clinical-stage biopharmaceutical company committed to realizing the
promise of precision medicines for the treatment of cancer. Our pipeline
consists of small molecule product candidates that target cancer signaling
pathways, and we intend to pair them with molecular or cellular diagnostics to
identify those patients most likely to respond to treatment. We intend to
advance our product candidates through a combination of internal development and
strategic partnerships and maintain significant development and commercial
rights.

Precision medicine is an approach to the treatment of cancer in which treatment
decisions are made based upon the presence or absence of specific molecular or
genetic biomarkers that characterize an individual’s tumor.  

Leave a Reply

Your email address will not be published. Required fields are marked *